Discontinuation of prolonged dual antiplatelet therapy for a dental extraction: A nearly-fatal decision

Stent thrombosis remains one of the most feared complications in patients with multiple stents implanted. In this clinical setting, optimal upfront dual antiplatelet therapy (DAPT) duration still remains controversial. Herein, we wish to report a case of life-threatening very-late stent thrombosis after DAPT temporary discontinuation, highlighting the prolonged increased thrombotic risk of complex angioplasty, even in otherwise low-ischemic risk patients according to recent recommendations. Our data are in line with novel information and might be useful in the pre-operative management of patients with complex percutaneous coronary intervention (PCI).

**Keywords:** Dual antiplatelet therapy • Percutaneous coronary intervention • Stable ischemic heart disease • Stent thrombosis • Cardiogenic shock • Glycoprotein IIb/IIIa inhibitors

**Case Report**

A 66-year-old hypertensive man presented with an acute anterior ST-elevation myocardial infarction (STEMI) and ensuing cardiogenic shock, five years after implantation of three drug-eluting (DES) stents in proximal left anterior descending (LAD), proximal first diagonal branch and circumflex artery (LCX) (Figures 1A-1D) for stable ischemic heart disease. The patient was asymptomatic since then; however, three days before his admission, he was advised to temporarily discontinue aspirin-clopidogrel DAPT for a minimal dental procedure (tooth extraction), and receive low molecular weight heparin (LMWH) as a five-day bridging therapy regimen.

The patient was transferred immediately to the catheterization laboratory; while coronary artery angiography (CAA) was in progress, he demonstrated devastating cardiogenic shock (noradrenaline dose ≤42 mcg/min) and electrical storm (numerous episodes of ventricular tachycardia/fibrillation), thus he was intubated and received several cycles of cardiopulmonary resuscitation and electrical cardioversion/defibrillation. CAA disclosed total left main artery (LMA) occlusion with a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 0, implying generalized acute stent thrombosis (Figure 1A, Online Video 1). While the patient was in premortal shock-

**Online Video 1:** Pre-interventional LAO coronary angiographic view with 30° cranial angulation, revealing a total LMA occlusion with TIMI flow grade of 0, as well as the three previously implanted drug-eluting stents in proximity to the lesion. LAO=left anterior oblique; LMA=left main artery; TIMI=Thrombolysis in Myocardial Infarction.
condition, two overlapping 3.5 × 18 mm Resolute™
zotarolimus-eluting stents (Medtronic Inc., Santa Rosa,
CA, USA) were successfully placed at distal LMA/
proximal LAD (Figure 1B), resulting in a TIMI flow
grade of 3 in LAD, yet extensive LAD thrombotic
remnants as well as a TIMI flow grade of 0 in LCX
(Figures 1C and 1D).

The patient was given 600 mg clopidogrel and 500
mg aspirin, tirofiban as bail-out therapy (25 mcg/
kg five-minute bolus, followed by 0.15 mcg/kg/min
18 h maintenance dose) and inotropic support with
levosimendan (0.05 μg/kg/min 3-day infusion), and
was transferred to coronary ICU. Remarkably, cardiac
function was promptly restored (left ventricular ejection
fraction was approximately 20% on ICU-admission,
>50% on ICU day-3), while central hemodynamics,
renal function and lacticemia were also gradually
improved; he was successfully extubated five days later,
and discharged home in an excellent clinical condition,
on medical therapy and aspirin-clopidogrel DAPT.

Our unique patient had previously received multiple
stents for stable ischemic heart disease [1]. Apart
from extensive coronary artery disease and greater
stent length, no additional factors associated with
increased ischemic/thrombotic risk were present [1].
According to recent recommendations [1], our patient
summarized a DAPT score of 1, which constitutes an
unfavorable benefit/risk ratio for prolonged DAPT. In
such circumstances, current evidence [1,2] questions
the role of prolonged (beyond 6-12 months) DAPT, as
protection against thrombosis may be outweighed by
increased hemorrhagic risk. However, our rare patient
was in low-bleeding risk [1]. In addition, he had a history
remarkable for increased procedural PCI complexity
(three stents implanted, three lesions treated, total stent
length >60 mm); in this subset of patients, novel data
provides evidence that longitudinal DAPT may bear
a significant clinical benefit [3]. In line with the latter,
our case highlights the critical role of complex PCI for
very late stent thrombosis and stresses the importance of
long-term DAPT in low-bleeding risk patients even in
the absence of other predisposing ischemic risk factors.

Dental extractions are considered as low-hemorrhagic
risk interventions that can safely be performed under dual
or even single antiplatelet therapy [4,5]. Additionally,
although recommended by several societies [6], heparin
bridging therapy is probably ineffective due to its minor
antiplatelet effects [7]. Bridging therapy with LMWH,
similar to what is recommended for patients on warfarin, has also been proposed by several societies during temporary interruptions in antiplatelet treatment in patients with coronary stents who need surgery [6,7]. Despite its safe profile, however, heparin is probably ineffective in preventing acute stent thrombosis, due to its minor antiplatelet effect [6,7]. In this respect, our case points out that effort should be made minor surgical interventions to be performed under ongoing antiplatelet treatment, while LMWH as an alternative antithrombotic therapy may be ineffective and critically increase peri-procedural thrombotic danger.

Medical literature has recently focused on very late stent thrombosis after DES implantation; yet, there is only sparse evidence-based therapeutic data and even far less knowledge in the outcomes of patients with stent thrombosis-induced STEMI and shock. Certainly, case reports may be of less clinical value in advancing scientific knowledge and reviewing current therapeutic algorithms in rare diseases. Although thrombolysis has been successfully utilized for stent thrombosis-induced STEMI [8], our rare case ex juvantibus emphasize the vital importance of the availability of catheterization laboratory and primary PCI in the clinical setting of devastating cardiogenic shock. In addition, in the event of problematic primary PCI and angiographic evidence of intracoronary thrombotic remnants, our report highlights the pivotal role of glycoprotein IIb/IIIa inhibitors as bailout therapy [9]. Finally, the non-catecholamine inotrope levosimendan may also play a crucial role in myocardial “salvage” in the extremely stressful condition of stent thrombosis-induced hemodynamic collapse; instead, exogenous catecholamines (e.g. dobutamine) may further precipitate the vicious-circle of catecholamine-mediated myocardial damage under such circumstances [10].

### Executive summary

Stent thrombosis remains one of the most feared complications in patients with multiple stents implanted. In this clinical setting, optimal upfront dual antiplatelet therapy (DAPT) duration still remains controversial.

Herein, we wish to report a case of life-threatening very-late stent thrombosis after DAPT temporary discontinuation, highlighting the prolonged increased thrombotic risk of complex angioplasty, even in otherwise low-ischemic risk patients according to recent recommendations.

Our data are in line with novel information and might be useful in the pre-operative management of patients with complex percutaneous coronary intervention (PCI).

### References